Article Text
Abstract
More than 25 years into the HIV epidemic, in excess of 2 million new infections continue to occur each year. HIV prevention research is crucial for groups at heightened risk for HIV, but the design and conduct of HIV prevention research with vulnerable populations worldwide raises considerable ethical challenges. The HIV Prevention Trials Network (HPTN) is a global collaborative network that conducts clinical and behavioural studies on non-vaccine interventions to reduce the transmission of HIV. In 2003, the HPTN developed ethical guidance to enhance the responsible conduct of its research activities and as a distinctive contribution to global research ethics. In what follows, the developments that motivated the drafting of a revised ethics document in 2009 are described, including the process by which that revision took place and some of the key differences between the HPTN ethics guidance and other relevant guidelines in the field.
- HIV infection and AIDS
- policy guidelines/institutional review boards/review committees
- position statements (of organisations/groups)
Statistics from Altmetric.com
Footnotes
For the HIV Prevention Trials Ethics Working Group
Funding Work on this document was supported by grant number U01 AI068619 from the National Institute of Allergy and Infectious Diseases (NIAID), with additional support from the National Institute on Drug Abuse (NIDA) and National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NIDA, NIMH, or the National Institutes of Health.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Addressing ethical challenges in HIV prevention research with people who inject drugs
- Implementing post-trial access plans for HIV prevention research
- HIV prevention research and global inequality: steps towards improved standards of care*
- The challenge of defining standards of prevention in HIV prevention trials
- Ethics of medical care and clinical research: a qualitative study of principal investigators in biomedical HIV prevention research
- Ethics guidance for HIV prevention trials
- HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women
- Characterisation of social support following incarceration among black sexual minority men and transgender women in the HPTN 061 cohort study
- Meeting the goal of concurrent adolescent and adult licensure of HIV prevention and treatment strategies
- Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partners